Title: Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Journal: Expert review of clinical pharmacology 20160101
Title: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Journal: The New England journal of medicine 20151105
Title: Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101
Title: Novel molecular targeted therapies for refractory thyroid cancer.
Journal: Head & neck 20120501
Title: Novel molecular targets for the therapy of castration-resistant prostate cancer.
Journal: European urology 20120501
Title: Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
Journal: Cancer discovery 20120301
Title: c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Journal: Gastroenterology 20111201
Title: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Journal: Molecular cancer therapeutics 20111201
Title: Novel therapies for metastatic castrate-resistant prostate cancer.
Journal: Journal of the National Cancer Institute 20111116
Title: Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Journal: Drugs of today (Barcelona, Spain : 1998) 20111101
Title: VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
Journal: Cancer research 20110715
Title: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701
Title: Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110615
Title: The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Journal: The Journal of clinical endocrinology and metabolism 20110601
Title: XL184 (cabozantinib) for medullary thyroid carcinoma.
Journal: Expert opinion on investigational drugs 20110301
Title: Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Journal: Endocrine journal 20110101
Title: Novel treatment of medullary thyroid cancer.
Journal: Current opinion in endocrinology, diabetes, and obesity 20091001
Title: You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.
Title: Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res, 2011, 17(12), 3943-3955.
Title: Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.
